Nicotinamide Riboside Dosage for Dogs: What Owners Should Actually Check

On this page

1. The decision fork most owners hit before they buy
2. A dog I saw whose owner had already done the math wrong
3. What the dosing evidence for dogs actually supports
4. What I actually tell owners to do with the dose on the label
5. The threshold that actually matters

Quick-check before you buy:

• No dose is standardized for dogs. Nicotinamide riboside (NR) dosing in commercial chews is set by the manufacturer, not by a body of canine-specific dosing trials.
• Bodyweight matters more than the label suggests. A dose calibrated for a 60-pound dog is not automatically right for a 12-pound dog, even if the label says “one chew daily.”
• Kidney function is the variable I ask about first. NAD+ precursors are processed renally, and dogs with existing kidney disease need veterinary sign-off before starting.
• Track four things for the first month: appetite, stool consistency, energy, and sleep. That’s the practical signal, not a lab panel you don’t have access to at home.
• A supplement is not a substitute for a workup. If you’re reaching for NR because your dog has slowed down, that slowing is the thing that needs a look first.

I want to walk through why each of those lines matters, because the checklist alone can be misread as permission to skip the thinking.

The decision fork most owners hit before they buy

Every owner who asks me about nicotinamide riboside is really asking two different questions at once, and they rarely notice they’re doing it. The first is “how much do I give my dog.” The second, underneath it, is “is this the right tool for what I’m noticing.” Those questions have different answers, and conflating them is where I see people get into trouble — not with toxicity, but with false reassurance.

NR is a NAD+ precursor: a compound the body converts into nicotinamide adenine dinucleotide, a coenzyme involved in hundreds of cellular reactions related to energy metabolism and repair, according to the NIH Office of Dietary Supplements. That’s a real, well-described biochemical role. What it is not is a dosing chart calibrated for dogs the way, say, a heartworm preventive is. Most of what we know about NR dosing comes from human trials, and translating that to a 20-pound terrier versus an 80-pound Labrador is not a straight-line calculation.

A dog I saw whose owner had already done the math wrong

A few years ago I examined a nine-year-old Cavalier King Charles Spaniel, about 17 pounds, whose owner had started her on a NAD+ chew after reading that it might help with “senior slowdown.” The dog had gone from taking the stairs without hesitation to pausing at the bottom most mornings, something the owner first noticed in early winter, over roughly six weeks. She’d been dosing at what the package listed as the standard adult serving, without adjusting for the dog’s small size, and she’d assumed the hesitation on the stairs was just early aging that the supplement would gradually smooth out. When I examined her, she had a grade II/VI heart murmur and mild discomfort on hip extension — findings unrelated to NAD+ levels, and findings the supplement was never going to address. The stair hesitation wasn’t a supplement-dosing problem. It was a diagnostic clue that had been quietly absorbed into a wellness routine instead of an exam room.

That’s the trap I want owners to avoid: using a supplement’s dosing question as a stand-in for the harder question of whether something new needs a look.

What the dosing evidence for dogs actually supports

Here’s the honest state of things. NR reliably raises NAD+-related biomarkers in mammalian studies, and human trials — including the NR-SAFE trial published in Nature Communications — have found high-dose NR to be generally well tolerated over extended use in people. That trial is useful context for the safety margin of the compound class, but it was not conducted in dogs, and its dosing range doesn’t translate directly to canine milligram-per-kilogram guidance.

On the dog side, a randomized controlled trial published in Scientific Reports evaluated a senolytic-plus-NAD+-precursor combination in senior dogs and found improved owner-assessed cognitive function. That’s a genuinely relevant, dog-specific data point — but it studied a combination product with a defined trial protocol, not a standalone NR dosing curve owners can extrapolate a “right amount” from. One well-designed trial on a combination formula tells you that approach is worth taking seriously; it doesn’t hand you a universal per-pound dose for a different single-ingredient product on a shelf.

This is the tempting shortcut owners reach for: if NAD+ helped in one dog study, and the human safety data looks reassuring, then more chews or a higher dose should be better. That shortcut misses the underlying question, which is whether the specific dose on the specific product in front of you was ever tested at your dog’s size, and whether your dog’s kidneys can process it without added strain. A compound being safe in aggregate doesn’t mean an untested dose is safe in your particular dog.

What I actually tell owners to do with the dose on the label

Don’t free-hand a “double dose for faster results” adjustment. If a product’s serving size doesn’t specify weight tiers, that’s information too — it tells you the formulation wasn’t built with small-breed and large-breed dosing differences in mind, and you should ask your vet before assuming the standard serving applies evenly across sizes.

Start at the labeled serving, not above it, and hold there for at least a few weeks before judging anything.

Watch stool and appetite in the first several days specifically, since digestive adjustment is the most commonly reported early response to NAD+ precursors, and it’s usually mild and temporary rather than a sign to escalate the dose to “push through” it.

If your dog has any history of kidney values trending up, get bloodwork before adding a NAD+ precursor rather than after, since these compounds are cleared renally and elevated creatinine has been observed at higher intake levels in the broader NAD+-precursor literature.

The threshold that actually matters

Here’s where I land, and where I’ll defend the position even against the obvious counterargument. The counterargument is: “NR looks safe in the studies we have, so why not just try it and see.” I understand the appeal — it’s low-friction, and most dogs tolerate it fine. But “probably safe at an untested dose” is not the same standard I’d apply to any other substance I recommend putting into a patient daily for months. The absence of documented harm in the literature we have is not the same as evidence of a correct dose for your specific dog.

I saw a similar pattern play out with a ten-year-old mixed-breed, closer to 45 pounds, whose owner had increased a NAD+ chew dose on her own after two weeks with no visible change, reasoning that if one chew a day wasn’t doing anything, two might. The dog’s appetite dropped over the following ten days, and stool became intermittently soft — not severe, but persistent enough that the owner finally called. Bloodwork showed nothing alarming, and the signs resolved within about a week of returning to the labeled dose. Nothing dangerous happened here, and I want to be clear that this one case isn’t evidence of a general risk. But it’s a clean illustration of the exact mechanism I worry about: self-escalated dosing on a compound without a dog-specific dose-response curve behind it, chasing a result the study data was never designed to promise.

The distinction that changes the decision isn’t “is NR risky.” For most healthy adult dogs at labeled doses, the available evidence is reassuring. The distinction is between normal variation in an aging dog — mild stiffness after a long walk, a slightly later start to the morning — and a change that’s new, progressive, or paired with another symptom. The first category is where a well-chosen supplement, taken at label dose with your vet aware of it, is a reasonable thing to try. The second category needs an exam before it needs a chew. If you’ve read this checklist and you’re still not sure which category your dog is in, that uncertainty is itself useful information: it’s the signal to book the visit rather than adjust the dose. For readers who want a look at how that reasoning holds up under pressure, from someone thinking through the emotional side of practicing this way daily, What Vet School Does Not Teach You About the Emotional Swings of Veterinary Life is worth your time.

Where this leaves us going forward: as more dog-specific NAD+ precursor trials publish, the dosing guidance will get sharper, and I’ll update how I counsel owners accordingly. Until then, the label dose, a patient few weeks of observation, and a vet who knows your dog’s kidney history remain the most defensible combination available.

Frequently asked questions

Is there an official nicotinamide riboside dosage for dogs?

No. There is no standardized, weight-based dosing chart for NR in dogs the way there is for many prescription medications. Commercial chews set their own serving sizes, and dog-specific dose-response data remains limited, so the labeled serving plus veterinary guidance is the most defensible starting point.

Can I increase the dose if I don't see results after a few weeks?

Self-escalating the dose isn't something I recommend. Hold at the labeled serving, give it a fair trial period, and talk to your vet before adjusting — especially if your dog has any history of kidney issues.

Sources

1. Niacin - Health Professional Fact Sheet — NIH Office of Dietary Supplements
2. A randomized, controlled clinical trial demonstrates improved owner-assessed cognitive function in senior dogs receiving a senolytic and NAD+ precursor combination — Scientific Reports
3. NR-SAFE: a randomized, double-blind safety trial of high dose nicotinamide riboside in Parkinson's disease — Nature Communications